Please describe your practice as a clinician,how many patients with wet AMD do you treat on a yearly basis? Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.

Please comment on the trial results main findings:-best corrected visual acuity (BCVA) (mean change from baseline of -1.3 letters) and central subfield thickness (CSFT) (mean change from baseline of +9.2 µm) in the OTX-TKI arm at 7 months, comparable with the aflibercept arm dosed every 8 weeks (mean change from BVCA baseline of -1 letter; mean change from CSFT baseline of +0.4 µm). -80% of subjects in the OTX-TKI arm were rescue-free up to 6 months and 73% of subjects in the OTX-TKI arm were rescue-free up to 7 months.

How likely is OTX-TKI to dethrone anti-VEGF injections as the golden standard of care for wet AMD, given those recent results?

How significant is the reported reduction in treatment burden?

How do the results from the latest interim analysis compare to earlier findings from the trial?

How does the competitive landscape for similar treatments look like, and how does the latest OTX-TKI data analysis position it within that landscape?

What is the potential for the recent data to look like a best in class treatment?